The comparative efficacy and risk of harms of the intravenous and subcutaneous formulations of trastuzumab in patients with HER2-positive breast cancer: a rapid review

ConclusionResults of studies indicate similar efficacy between the two routes of administration. The higher rates of adverse events for SC administration were mainly attributable to injection site –related events. The clinical decision of whether to administer trastuzumab SC or IV requires the consideration of several factors and should be determined individually.
Source: Systematic Reviews - Category: International Medicine & Public Health Source Type: research